Identifying biomarkers for liver cancer in patients with Hepatitis C
Official title: Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development
Run by Centro di Riferimento Oncologico - Aviano · NCT06718530 · Data updated 2026-11-12
This study is trying to find specific markers in the blood of people with chronic Hepatitis C to see if they can help spot liver cancer early.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 4 sites (Aviano, Pordenone and 3 other locations) |
| Status | Recruiting |
| Started | May 13, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | December 5, 2024 |
| Trial ID | NCT06718530 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with chronic Hepatitis C infection, fibrosis, cirrhosis, or HCV-associated HCC.
✕Probably not a fit
Patients undergoing treatment for other oncological diseases or those with immunodepression may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize immune genotypes and antibody profiles in patients with chronic Hepatitis C virus (HCV) infection. It focuses on evaluating novel circulating biomarkers, including antibodies to specific HCV proteome peptides and the expression of interferon lambda 4 (IFNL4). The study will assess the genetic diversity of immune response markers that may predict the development of hepatocellular carcinoma (HCC) years before diagnosis. By understanding these biomarkers, the research seeks to improve surveillance and early detection of liver cancer in at-risk populations.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of liver cancer in patients with Hepatitis C.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for liver cancer, but this approach focusing on specific immune responses is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥18 years with the presence of chronic infection, fibrosis, cirrhosis or HCV- associated HCC * Patients able to understand and willing to sign the of informed consent * Patients to answer the questions in the questionnaire of enrollment Exclusion Criteria: * Treatment for other oncological diseases * Immunodepression congenital or acquired (HIV, organ transplantation, pharmacological)
Where it's running
-
Centro di Riferimento Oncologico (CRO) di aviano-IRCCS
Aviano, Pordenone, Italy Recruiting -
AORN S.Anna e S. Sebastiano, Via F. Palasciano
Caserta, Italy Recruiting -
Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale"
Naples, Italy Recruiting -
Dip. Univ. Clin. di Scienze mediche, chirurgiche e della salute Università di Trieste
Trieste, Italy Recruiting
Study contacts
- Principal investigator: Valli De Re, PhD — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Valli De Re, PhD
- Email: vdere@cro.it
- Phone: +39 0434 659672
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GPS tracking to support Hepatitis C treatment for people experiencing unsheltered homelessness.
This trial tests whether giving GPS trackers to people with Hepatitis C who are living unsheltered and receiving street medicine helps them stick to their daily hepatitis C medication.
-
Germinal center immune response in chronic hepatitis B
We will see if the structure and B-cell activity in germinal centers differ between people with chronic hepatitis B and people without by analyzing blood and discarded surgical tissues.
-
GIGA-2339: safety and drug behavior testing in people with chronic hepatitis B
This trial tests single and multiple IV doses of GIGA-2339 versus placebo to see if they are safe and well tolerated in adults with chronic hepatitis B.
-
Hepatitis B vaccination for newborns after surgery
This study looks at how safe and effective it is to give hepatitis B vaccinations to newborns who have had surgery, to help find the best timing for these shots.
-
Registry for patients with hepatitis B virus infection
This study is collecting information from people with hepatitis B to better understand the virus and find out who might be interested in trying new treatments like vaccines.
-
Evaluating new biomarkers for chronic Hepatitis B infection management
This study is testing new blood markers to see if they can help doctors better manage chronic Hepatitis B and predict serious health issues for patients receiving care at a hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.